---
id: poliovirus_316
category: organisms
tags: [poliovirus, poliomyelitis, IPV, OPV, VAPP, post-polio-syndrome, eradication, picornavirus]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Poliovirus

**Q:** What are the two polio vaccines, their advantages/disadvantages, and the status of polio eradication?

**A:**

**Overview:**
- **Picornavirus** (enterovirus genus)
- Three serotypes: Type 1, 2, 3
- **Type 2 eradicated** (2016); types 1 and 3 persist in Pakistan/Afghanistan

**Vaccines:**

| Feature | **IPV** (Inactivated Polio Vaccine, Salk) | **OPV** (Oral Polio Vaccine, Sabin) |
|---------|-------------------------------------------|--------------------------------------|
| **Type** | Killed virus (injectable) | Live attenuated virus (oral) |
| **Immunity** | **Systemic** (prevents viremia/CNS disease) | **Mucosal + systemic** (intestinal immunity prevents transmission) |
| **Advantages** | **NO risk of VAPP** | **Herd immunity** (intestinal immunity stops transmission); easier administration |
| **Disadvantages** | Does NOT induce intestinal immunity (vaccinated individuals can still shed virus) | **VAPP risk**: ~**3 cases per 1 million doses** |
| **Current use** | **US, Europe** (since 2000) | Low-/middle-income countries (eradication efforts) |

**Clinical Polio:**
- Most infections **asymptomatic** (95%)
- **Minor illness** (4-8%): Fever, sore throat, GI symptoms
- **Aseptic meningitis** (1-5%)
- **Paralytic polio** (<1%): **Asymmetric flaccid paralysis** (anterior horn cell destruction); bulbar involvement can cause respiratory failure

**Vaccine-Associated Paralytic Poliomyelitis (VAPP):**
- OPV virus **reverts** to neurovirulent form
- **3 per 1 million doses** OPV (vs 5,000 per 1 million wild polio infections)
- Clinically indistinguishable from wild polio

**Circulating Vaccine-Derived Poliovirus (cVDPV):**
- OPV virus circulates in under-vaccinated populations, mutates
- **2024**: **312 paralytic cases** from cVDPV (21 countries)
- **Type 2 removal from OPV (2016)** intended to stop type 2 VDPV; **"unqualified failure"** (GPEI report)

**Post-Polio Syndrome:**
- New weakness/fatigue **decades** after acute polio
- Occurs in ~25-50% of polio survivors
- Gradual decline in motor function

**Eradication Status (2024):**
- **Wild polio**: **Persists only in Pakistan/Afghanistan** (4 cases in 2024)
- **cVDPV**: Major challenge (312 cases, 21 countries in 2024)

**Key Points:**
- **IPV** prevents paralysis (no VAPP) but doesn't stop transmission (used in US)
- **OPV** creates herd immunity (stops transmission) but causes VAPP (3/million doses)
- Wild polio nearly eradicated; **cVDPV** now bigger problem

**Mnemonic - "IPV = I Prevent Viremia; OPV = Oral Protects Village"**: IPV (systemic), OPV (mucosal + herd immunity)

**Pearl:** OPV causes 3 cases of VAPP per million doses but is superior for eradication (intestinal immunity stops transmission). Wild polio persists only in Pakistan/Afghanistan; circulating vaccine-derived poliovirus (cVDPV) caused more cases in 2024 (312) than wild virus (4).

**Media:**

**Sources:** [Science.org Polio Vaccine Policy Failure 2024], [PMC10424844 - VAPP Epidemiology], [CHOP Polio Vaccine Education], [WHO/GPEI Polio Eradication Updates 2024]
